The global radiopharmaceutical CDMO market is set to grow significantly over the next ten years, as pharmaceutical and biotech companies increasingly implement target-specific radiopharmaceuticals in their practice relying heavily on contract development and manufacturing organizations (CDMOs) for support. “According to a recent study by SNS Insider, the global Radiopharmaceutical CDMO Market size valued at USD 3.27 billion in 2025, is anticipated to grow to USD 8.14 billion by 2035, registering a CAGR of 9.54% over the 2026–2035 forecast period.”
The developments in precision oncology and increasing adoption of radiopharmaceutical drugs in clinical applications, alongside growing investments in manufacturing technologies have resulted in significant changes being introduced into the contract manufacturing industry worldwide. Because of the accelerated development of targeted radionuclide therapies, there is an increasing demand for skilled manufacturing organizations to meet the complex manufacturing needs involved with such therapies.
Pharmaceutical companies are now partnering with CDMOs to expedite development, allow for efficient manufacturing processes and improve commercial availability by way of strict manufacturing conditions high regulatory requirements for radiopharmaceutical products.
To Get Detailed Insights on the Radiopharmaceutical CDMO Market – Request a Free Sample Report
Precision Oncology Continues to Drive Manufacturing Demand
Technological advances in targeted therapy for cancers are creating new opportunities within the radiopharmaceuticals manufacturing industry. Growing interest in precision medicine is prompting drugmakers to contemplate drugs that can directly dispense treatment but minimize exposure to adjacent healthy tissue.
In parallel, investments into nuclear medicine infrastructure and isotope manufacturers with advance manufacturing technologies are improving global capacity. Continued advancements in radiochemistry methodological development, automated production technology, and quality control methods will promote sustainable growth of the industry in the future.
As radiopharmaceutical pipelines continue to mature, specialized manufacturing expertise is becoming an increasingly valuable competitive advantage for drug developers worldwide.
Key Market Findings Highlight Emerging Opportunities
Among radioisotope categories, Lutetium-177 (Lu-177) is expected to contribute 29.00% revenue share by 2025 and be the most progressively growing segment with a CAGR of 14.24% till through 2035 as targeted radioligand therapy treatments continue to gain acceptance in the clinical space.
By service type, clinical manufacturing accounted for 31.00% of total revenue in 2025, as majority of the companies have been facing an increase in demand due to radiopharmaceutical product candidates entering into clinical development. Meanwhile, fill-finish & packaging are expected to be the fastest-growing segments, with a CAGR of 12.42%.
Application analysis highlights the market's strong oncology focus. The oncology segment accounted for 48.00% of the total revenue in 2025, and the segment is additionally anticipated to expand at a sustained compound annual growth rate (CAGR) of 11.44%.
From an end-user perspective, pharmaceutical companies occupied 32.00% share of revenue worldwide in 2025 and segment is anticipated to register the highest growth rate of all – compound annual growth rate (CAGR) of 14.98%.
An Infographic Representation of the Global Radiopharmaceutical CDMO Market
Manufacturing Innovation Supports Industry Expansion
Radiopharmaceutical manufacturing is one of the greatest beneficiaries due to technology investments in manufacturing process as well as reliability and compliance of supply chain. The manufacturers are setting up dedicated manufacturing units that will support the complex manufacturing processes along with quality systems to ensure compliance on the evolving regulations in global market.
Efficient operations and safe handling of radiopharmaceutical products have been contributed by automation technology, containment technology and manufacturing platform. These improvements are thought to help manufacturability at high demand.
Regional Markets Continue to Expand
In 2025, North America accounted for a 43.00% share in the global market revenue owing to advanced infrastructure in nuclear medicine, high pharmaceutical research activities and rising commercialization of radiopharmaceutical treatment targets. The sector has been further reinforced by investments in capacity manufacturing and dedicated manufacturing units.
In comparison, The Asia Pacific region is expected to be the fastest-growing regional market, with a CAGR of 13.65% until 2035. The region offers significant opportunities owing to the increasing healthcare infrastructure, rising oncology research activities, investments in nuclear medicine, and partnerships between pharmaceutical companies and manufacturing units.
Leading Companies Strengthen Global Manufacturing Capabilities
Due to the growing global pipeline of radiopharmaceutical therapy targets, competitive forces in the radiopharmaceutical CDMO market are rising with investment into facility expansion and isotope production, new technology, and partnerships.
Key companies operating in the global Radiopharmaceutical CDMO Market include Curium, Eckert & Ziegler, ITM Isotope Technologies Munich SE, NorthStar Medical Radioisotopes, Cardinal Health, SOFIE Biosciences, PharmaLogic Holdings, SHINE Technologies, Telix Pharmaceuticals, and Jubilant Radiopharma.
An SNS Insider analyst Parry Kardani commented, "Growing adoption of precision oncology and targeted radionuclide therapies is fundamentally transforming the radiopharmaceutical manufacturing landscape. CDMOs with expertise in isotope handling, regulatory compliance, and commercial-scale production will be well positioned to capitalize on the industry's long-term growth opportunities."
About the Author
Get in touch
